Close

Form 8-K Augmedix, Inc. For: Aug 08

August 8, 2022 4:09 PM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
0001769804 false 0001769804 2022-08-08 2022-08-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): August 8, 2022

 

 

 

AUGMEDIX, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-56036   83-3299164

(State or other jurisdiction

of incorporation)

 

(Commission File Number)

 

(I.R.S. Employer

Identification No.)

 

111 Sutter Street, Suite 1300, San Francisco, California 94104

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (888) 669-4885

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   AUGX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On August 8, 2022, Augmedix, Inc., a Delaware corporation (the “Company”), released its financial results for the second quarter ended June 30, 2022. The press release announcing the release of financial results is furnished as Exhibit 99.1 and is incorporated herein by reference.

 

Item 7.01. Regulation FD Disclosure.

 

On August 8, 2022, a presentation entitled “Augmedix Investor Presentation August 2022” was made available on the Presentations page of the Company’s website at https://ir.augmedix.com/company-information/presentations. The presentation is furnished as Exhibit 99.2 and is incorporated herein by reference.

 

The information set forth in Items 2.02 and 7.01 of this Current Report on Form 8-K and in the attached Exhibits 99.1 and 99.2 are deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release dated August 8, 2022.
     
99.2   Augmedix Investor Presentation August 2022.
     
104   Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AUGMEDIX, INC.
     
Dated: August 8, 2022 By: /s/ Paul Ginocchio
    Paul Ginocchio
    Chief Financial Officer

 

 

2

 

Exhibit 99.1

 

 

Augmedix Reports Second Quarter 2022 Financial Results

 

SAN FRANCISCO, Calif. – August 8, 2022 – Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today reported financial results for the three months ended June 30, 2022.

 

“This quarter, we continued to see good momentum and are pleased with our strong start to 2022. We remain focused on our path to profitability as we drive enterprise customer expansion, make good progress on our automation and new product development, and scale our business model. The operating leverage inherent in our business model helps us realize economic benefits as we grow the business. As a result, we now have over two years of operating runway based on cash on hand and availability under our new debt facility,” said Manny Krakaris, Chief Executive Officer of Augmedix.  “As physician retention, burnout, and staffing shortages continue to impact healthcare organizations, our pipeline continues to expand, leading to continued revenue growth and record bookings. We are encouraged by our progress so far in 2022 and are set up to deliver a strong second half.”

 

Second Quarter 2022 Financial and Operational Highlights

 

All comparisons, unless otherwise noted, are to the three months ended June 30, 2021.

 

Total revenue was $7.3 million, an increase of 42% compared to $5.2 million.

 

Dollar-based Net Revenue Retention was 131% for our Health Enterprise customers compared to 129%.

 

Average Clinicians in Service grew 49% YoY.

 

GAAP Gross Margin was 43.7% compared to 46.6%. Non-GAAP Gross Margin was 44.0% compared to 45.2%.

 

GAAP Operating Expenses were $9.3 million, up 44% compared to $6.4 million. Non-GAAP Operating Expenses, which excludes stock-based compensation and one-time items in both periods, grew 33% to $8.8 million compared to $6.6 million.

 

GAAP Net Loss was $7.4 million compared to $4.6 million.

 

EBITDA losses were $6.8 million compared to $3.8 million. Adjusted EBITDA losses were $5.3 million compared to $4.0 million, which excludes the Stock-based compensation expense in both periods, the Loss on extinguishment of the prior debt facility in 2022, and the negotiated reduction of previously invoiced transaction-related expenses, related to the October 2020 transactions, and lease provision write-off in 2021.

 

Cash and restricted cash as of June 30, 2022, was $30.8 million compared to $16.7 million as of June 30, 2021.

 

Non-GAAP Operating Expenses, Non-GAAP Gross Margin, EBITDA and Adjusted EBITDA are Non-GAAP financial measures. Please see “Non-GAAP Financial Measures” below and the Reconciliation of the GAAP to non-GAAP Financial Measures table below in this press release.

 

Conference Call

 

Augmedix will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on Monday, August 8, 2022, to discuss its second quarter 2022 financial results. The conference call can be accessed by dialing +1-877-407-3982 for U.S. participants or +1-201-493-6780 for international participants and referencing conference ID # 13730853. Interested parties may access a live and archived webcast of the event on the “News and Events” section of the Company’s website at: https://ir.augmedix.com/news-events.

 

 

 

 

Definition of Key Metrics

 

Dollar-Based Net Revenue Retention: We define a “Health Enterprise” as a company or network of doctors that has at least 50 clinicians currently employed or affiliated that could utilize our services. Dollar-based net revenue retention is determined as the revenue from Health Enterprises as of twelve months prior to such period end as compared to revenue from these same Health Enterprises as of the current period end, or current period revenue. Current period revenue includes any expansion or new products and is net of contraction or churn over the trailing twelve months but excludes revenue from new Health Enterprises in the current period. We believe growth in dollar-based net revenue retention is a key indicator of the performance of our business as it demonstrates our ability to increase revenue across our existing customer base through expansion of users and products, as well as our ability to retain existing customers.

 

Average Clinicians in Service: We define a clinician in service as an individual doctor, nurse practitioner or other healthcare professional using our services. We average the month-end number of clinicians in service for all months in the measurement period and the number of clinicians in service at the end of the month immediately preceding the measurement period. We believe growth in the number of clinicians in service is an indicator of the performance of our business as it demonstrates our ability to penetrate the market and grow our business.

 

About Augmedix

 

Augmedix, Inc. (Nasdaq: AUGX) provides automated medical documentation and data services to large healthcare systems and physician practices, supporting medical offices, clinics, hospitals, emergency departments, and telemedicine nationwide. The Company’s Ambient Automation Platform converts the natural conversation between physicians and patients into timely and comprehensive medical notes and performs a suite of related data services. These services relieve physicians of administrative burdens to enable more time for patient care. Augmedix’s proprietary platform uses automatic speech recognition, natural language processing and clinical datasets to capture the ambient visit conversation and generate a structured medical note. The structured medical note data is then used to deliver additional data services. Quality is assured by trained medical documentation specialists. To learn more about Augmedix, visit augmedix.com.

 

Non-GAAP Financial Measures

 

To supplement our consolidated financial statements, which are prepared and presented in accordance with GAAP, we use the following non-GAAP financial measures: Non-GAAP gross profit, adjusted gross margin, Non-GAAP Operating Expenses, EBITDA, and adjusted EBITDA. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

 

We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our recurring core business operating results, like one-time transaction costs related to the reverse merger and OTC listing. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to our historical performance and liquidity as well as comparisons to our competitors’ operating results. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the health of our business.

 

There are a number of limitations related to the use of non-GAAP financial measures. We compensate for these limitations by providing specific information regarding the GAAP amounts excluded from these non-GAAP financial measures and evaluating these non-GAAP financial measures together with their relevant financial measures in accordance with GAAP.

 

For more information on the non-GAAP financial measures, please see the Reconciliation of GAAP to non-GAAP Financial Measures table in this press release. This accompanying table includes details on the GAAP financial measures that are most directly comparable to Non-GAAP financial measures and the related reconciliations between these financial measures.

 

2

 

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” that involve a number of risks and uncertainties. Words such as “believes,” “may,” “will,” “estimates,” “potential,” “continues,” “anticipates,” “intends,” “expects,” “could,” “would,” “projects,” “plans,” “targets,” “excited,” “optimistic,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our momentum in 2022; our focus on our path to profitability as we drive enterprise customer expansion; our progress on automation and new product development and our scaling of our business model; our operating leverage helping us realize economic benefits as we grow the business; our operating runway; our pipeline expansion leading to continued revenue growth and record bookings; and statements regarding being encouraged by our progress so far in 2022 and being set up to deliver a strong second half. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in our most recent Form 10-K filed with the U.S. Securities and Exchange Commission on March 30, 2022 as well as other documents that may be filed by us from time to time with the U.S. Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: our expectations regarding changes in regulatory requirements; our ability to interoperate with the electronic health record systems of our customers; our reliance on vendors; our ability to attract and retain key personnel; the competition to attract and retain remote documentation specialists; anticipated trends, growth rates, and challenges in our business and in the markets in which we operate; our ability to further penetrate our existing customer base; our ability to protect and enforce our intellectual property protection and the scope and duration of such protection; developments and projections relating to our competitors and our industry, including competing dictation software providers, third-party, non-real time medical note generators and real time medical note documentation services; and the impact of current and future laws and regulations Past performance is not necessarily indicative of future results. The forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

 

Investors:

 

Caroline Paul

Gilmartin Group

[email protected]

 

Media:

 

Kaila Grafeman

Augmedix

[email protected]

 

3

 

 

AUGMEDIX, INC.

Condensed Consolidated Statements of Operations

(Unaudited, in thousands except Average Clinicians in Service)

 

   Three Months Ended 
   June 30, 
   2022   2021 
Revenue  $7,333   $5,173 
Cost of revenues   4,131    2,761 
Gross profit   3,202    2,412 
Operating expenses          
General and administrative   4,172    3,220 
Sales and marketing   2,432    1,728 
Research and development   2,649    1,499 
Total operating expenses   9,253    6,447 
Loss from operations   (6,051)   (4,035)
           
Total other income (expenses), net   (1,396)   (602)
Net loss  $(7,447)  $(4,637)
           
Average Clinicians in Service   1,040    700 

 

4

 

 

AUGMEDIX, INC.

Reconciliation of GAAP to Non-GAAP Financial Measures

(Unaudited, in thousands)

 

   Three Months Ended 
   June 30, 
Stock Based Compensation Expense  2022   2021 
Cost of revenues  $24   $7 
General and administrative   344    174 
Sales and marketing   42    16 
Research and development   81    42 
Total stock-based compensation expense  $491   $239 
           
Net loss  $(7,447)  $(4,637)
Interest expense   385    605 
Tax   2    50 
Depreciation and Amortization   215    165 
EBITDA  $(6,845)  $(3,817)
Add: Stock-based compensation expense   491    239 
Add: Loss on extinguishment   1,097    - 
Less: Lease provision write-off   -    (259)
Less: Transaction related expense write-off   -    (208)
Adjusted EBITDA  $(5,257)  $(4,045)
           
GAAP Cost of Revenues  $4,131   $2,761 
Less: Stock-based compensation expense   (24)   (7)
Add: Lease provision write-off   -    82 
Non-GAAP cost of revenues   4,107    2,836 
Non-GAAP Gross Profit  $3,226   $2,337 
Non-GAAP Gross Margin   44.0%   45.2%
           
GAAP Operating Expenses  $9,253   $6,447 
Less: Stock-based compensation expense   (467)   (232)
Add: Lease provision write-off   -    177 
Add: Transaction related expense write-off   -    208 
Non-GAAP Operating Expenses  $8,786   $6,600 

 

5

 

 

AUGMEDIX, INC.

Condensed Consolidated Balance Sheet

(Unaudited, in thousands)

 

   June 30,   December 31, 
   2022   2021 
Assets        
Cash & restricted cash  $30,778   $41,587 
Accounts receivables, net   4,697    7,178 
Other assets   5,088    2,918 
Total asset  $40,563   $51,683 
           
Liabilities & Stockholders’ Equity          
Liabilities          
Accounts payable  $1,584   $1,365 
Deferred revenue   5,863    6,238 
Loan payable   14,932    14,837 
Other liabilities   7,017    5,559 
Total liabilities  $29,396   $27,999 
Stockholders’ equity  $11,167   $23,684 
Total liabilities & stockholders’ equity  $40,563   $51,683 

 

6

 

 

AUGMEDIX, INC.

Condensed Consolidated Statement of Cash Flows

(Unaudited, in thousands)

 

   Six Months Ended 
   June 30, 
   2022   2021 
         
Cash flows from operating activities  $(8,856)  $(7,853)
Cash flows from investing activities   (615)   (318)
Cash flows from financing activities   (1,248)   1,884 
Effect of exchange rate changes on cash and restricted cash   (90)   (1)
Net decrease in cash  $(10,809)  $(6,288)
Cash and restricted cash at the beginning of the period  $41,587   $22,973 
Cash and restricted cash at the end of the period  $30,778   $16,685 

 

 

7

 

Exhibit 99.2

 

Investor Presentation August 2022

 

 

This presentation includes forward - looking statements. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding the Company’s future financial position, business strategy and plans and objectives of management for future operations, are forward - looking statements. Forward - looking statements use words like “believe,” “plan,” “expect,” “intend,” “will,” “would,” “anticipate,” “estimate,” and similar words or expressions in discussions of the Company’s future operations, financial performance or the Company’s strategies. These statements are based on current expectations or objectives that are inherently uncertain. In light of these uncertainties, and the assumptions underlying the expectations and other forward - looking statements expressed, the forward - looking events and circumstances discussed in the accompanying materials may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward - looking statements. The Company’s actual results could differ materially from those stated or implied in forward - looking statements due to a number of factors, including but not limited to, those factors described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recent Form 10 - K and Form 10 - Q filed with the Securities and Exchange Commission, and similar disclosures in subsequent reports filed with the SEC. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward - looking statements: the Company’s expectations regarding changes in regulatory requirements; the Company’s ability to interoperate with the electronic health record systems of its customers; the Company’s reliance on vendors; the Company’s ability to attract and retain key personnel; the competition to attract and retain remote documentation specialists; anticipated trends, growth rates, and challenges in the Company’s business and in the markets in which the Company operates; the Company’s ability to further penetrate its existing customer base; the Company’s ability to protect and enforce its intellectual property protection and the scope and duration of such protection; developments and projections relating to the Company’s competitors and the Company’s industry, including competing dictation software providers, third - party, non - real time medical note generators and real time medical note documentation services; the impact of current and future laws and regulations; and the impact of the COVID - 19 crisis on the Company’s business, results of operations and future growth prospects. Past performance is not necessarily indicative of future results. The forward - looking statements included in this presentation represent the Company’s views as of the date of this presentation. The Company anticipates that subsequent events and developments will cause the Company’s views to change. The Company undertakes no intention or obligation to update or revise any forward - looking statements, whether as a result of new information, future events or otherwise. These forward - looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this presentation. This presentation includes information related to market opportunity as well as cost and other estimates obtained from internal analyses and external sources. The internal analyses are based upon management’s understanding of market and industry conditions and have not been verified by independent sources. Similarly, the externally sourced information has been obtained from sources the Company believes to be reliable, but the accuracy and completeness of such information cannot be assured. Neither the company, nor any of its respective officers, directors, managers, employees, agents, or representatives, undertake to update any of such information or provide additional information as a result of new information or future events or developments. Disclaimer

 

 

The Healthcare Dilemma There are now numerous demands competing for the physician’s attention at the point of care. Chief among those is electronic documentation . Today’s point - of - care delivery policies and technologies have become an intrusion, creating a virtual “wall” between physician and patient. This has resulted in a significant reduction in productivity for the industry and led to unprecedented levels of physician burnout and patient dissatisfaction .

 

 

Augmedix Mission & Vision Our mission is helping physicians see the patient, not the technology, minimizing distractions and enabling physicians and patients to truly connect at the point of care. Our vision is to connect terabytes of point - of - care data in a way no other company has done before in order to deliver rapid, actionable insights that can improve outcomes for tens of millions of patients around the world .

 

 

Augmedix Benefits Save up to 3 hours per day Boost productivity by as much as 20% 40% improved work - life satisfaction

 

 

44% YoY Real - time and asynchronous virtual medical documentation for clinicians Connect clinicians with Augmedix Ambient Automation Platform through mobile devices and proprietary software Comprehensive and flexible solution capable of being delivered at scale to >57,000 addressable physicians Let physicians focus on what matters most: patient care $7.3M Q2 2022 Revenue 131% Q2 2022 YoY Net Revenue Retention 20+ Health Systems Served 2.5M+ Notes Completed Annually Augmedix at a Glance 1H 21 1H 22 $14.3 Revenue ($ in millions) $10.0

 

 

Key Healthcare Macro Tailwinds Growing doctor burnout and staffing shortages Health systems’ rising need for increased efficiency and capacity at scale COVID - 19 catalyst for virtual solutions Leading to increased demand to reduce Electronic Health Record (EHR) burden Driving more investments in digital solutions Accelerating adoption for virtual documentation

 

 

Augmedix Eases the EHR Burden on Providers & Creates System Efficiencies Natural Conversation Enhanced Documentation Physician - Patient Augmedix Ambient Automation Platform LIVESTREAM Electronic Health Record Medical documentation uploaded for physician’s sign - off Natural Language Processing (NLP ) Data Services Automatic Speech Recognition (ASR) Machine Learning Two - way communication

 

 

Driving a $6 Billion Market Opportunity for Augmedix ~295,000 ¹ Addressable Physicians in U.S. $6B U.S. Market Opportunity >57,000¹ Addressable Physicians $1B+ Expansion Opportunity within Existing Customers United States India Bangladesh Sri Lanka Opportunity (1) Company estimates out of a total of more than 1.1M U.S. Clinicians. Select Current Customers Major Health Systems Scale Today 4 Countries 5M+ Notes to Date 40K+ Notes / Week

 

 

Comprehensive medical notes and live clinical services delivered synchronously. • Medical Documentation • Synchronous Two - Way Communication trained Specialist • Order Support • Referral Support • Reminder Support Real - Time and Asynchronous Offerings Provide Flexibility, Expand the TAM, and Generate a High - Win Rate vs Competitors 2014 Launch Upsell / Migrate Organized relevant chart details to prepare for upcoming visits. • Patient Demographic Information • Medication Changes since Last Visit 2022 Launch Comprehensive medical notes delivered asynchronously. • Medical Documentation 2020 Launch Upsell / Migrate Upsell / Migrate

 

 

Augmedix Ambient Automation Platform Ambient conversation Messages Reminders Medical Note Chart Prep After - Visit Summary Coding ASR+ EHR Integration Augmedix NLP Notebuilder Builder Manager Preferences Metadata Building Block approach combines: • Automated speech recognition • Natural language processing • Clinical datasets 35+ Specialties Multiple healthcare settings: • Clinic, ER, urgent care, telehealth, inpatient, nursing home 500+ condition models • Manages clinician preferences • EHR integration via HL7/FHIR Leverages metadata for new services: • Chart prep • Real - time coding • Health data analytics

 

 

Quality Assured Ambient Conversation Physician - Patient Automated Note Creation Flow Notebuilder Automatic Speech Recognition (ASR) Physician: Nice to meet you. What brings you in today? Patient: I got a headache yesterday and it just won’t go away. Physician: Any fever or chills? Patient: No, just the headache and a sore throat. I’m taking Tylenol but it’s not helping. Physician : Let’s start you on Ibuprofen, 800 mg, for 3 - 5 days . headache fever sore Natural Language Processing (NLP) Physician: Nice to meet you. What brings you in today? Patient: I got a yesterday and it just won’t go away. Physician: Any or chills? Patient: No, just the headache and a throat. I’m taking Tylenol but it’s not helping. Physician : Let’s start you on Ibuprofen, 800 mg, for 3 - 5 days . Medical Note Electronic Health Record HPI The patient is a 55 year old female presenting today for: Headache Headache She reports onset 1 day ago. She denies fever or chills. Patient is taking Tylenol without relief. PE Mouth and throat: Red and swollen turbinate, throat otherwise normal. A/P Headache New, acute. Uncontrolled. Patient start ibuprofen 800 mg for 3 - 5 days. Headache 1 Organize Build Review HPI ROS PE A/P Coding COMPLAINTS Timing ONSET TIMING hours days weeks 1 constantly frequently intermittently Medication flutcasone levofloxacin ibuprofen DOSAGE FREQUENCY 3 - 5 days 400 mg 800 mg Sore Throat 2

 

 

Documentation Market Landscape Dictation/Transcription Asynchronous Documentation Synchronous Documentation Price Low DAX Dragon Fluency Direct SA Physician Burden Remote In - Person Remote Remote High

 

 

Augmedix’s Differentiated & Flexible Offerings Self Entry / Status Quo Dictation / Transcription In - Person Scribing Automated Medical Documentation (Asynchronous) Automated Medical Documentation (Synchronous with Live Support) Ambient / Natural Conversation Real - Time, Referral Support, Order Support, Reminder Support Scalable / Tech - Enabled Time Savings Today’s Leading Solutions

 

 

Q2 2022 Financial Summary Note: Fiscal years are audited through December 31, 2021. Quarterly results are unaudited. (1) Q2 2022 excludes one - time benefit from a previous office lease provision. (2) LTM through 2Q 2022. The Lifetime Value (LTV) of Augmedix Live is calculated by ARPU / (Annual Churn Percentage) x expected contribution margin. Customer Acquisition Cost (CAC) is the sales and marketing spend in the previous quarter divided by the number of new clinicians sold in the most recent quarter plus the onboarding costs in the most recent quarter divided by the number of go lives in the most recent quarter. (3) LTM through Q2 2022. Payback period in months is calculated by CAC divided by the expected contribution profit in the first - year x 12. (4) Based on current period revenue including any expansion or new services and is net of contraction or churn compared to the previous period one year ago but excludes revenue from new Health Enterprises for the current period. $40M capital raised in Oct 2021, plus debt refinancing in May 2022, provides significant operating runway to execute strategy LTV/CAC (2) : 5x Payback Period (3) : ~14 months $4.8 $5.6 $5.2 $6.6 Accelerating Revenue Growth ($ in millions) $7.3 $7.0 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 $2.5 $2.1 $2.9 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 $2.4 Improving Gross Profit ($ in millions) $3.1 Q2 2022 $3.2 131% Net Revenue Retention Rate (4) YoY 42% YoY 37%

 

 

Highly Experienced Management Team Sandra Breber Chief Operating Officer Paul Ginocchio Chief Financial Officer Rashed Noman Country Manager, Bangladesh Ian Shakil Co - Founder & Chief Strategy Officer Jonathan Hawkins Chief Revenue Officer Davin Lundquist Chief Medical Officer Saurav Chatterjee Chief Technology Officer Manny Krakaris Chief Executive Officer

 

 

Investment Highlights Broadest offerings that are differentiated and flexible for virtual documentation: Ambient, Mobile, Remote, Synchronous & Asynchronous Increasing physician productivity and optimizing reimbursement Leading health system customer base with high Net Revenue Retention Attractive scalable business model with compelling unit economics Building on AI - driven core platform to deliver automated add - ons and drive growth and efficiency

 



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings